Jennewein Biotechnologie develops new fermentation technology for human milk oligosaccharides and expands its product portfolio

Rheinbreitbach (ots) - Jennewein Biotechnologie GmbH announces the
introduction of a total biosynthesis approach for the production of
human milk oligosaccharides (HMOs). Currently the production of HMOs
by fermentation requires lactose as a starting material. Lactose is a
costly dairy by-product and is difficult to handle in large-scale
fermentations.

Jennewein Biotechnologie has recently developed processes for the
complete biosynthesis of complex HMOs from simple carbon sources
rather than lactose. "The introduction of total biosynthesis concepts
makes the fermentation process more robust and also more cost
effective," states Dr. Stefan Jennewein (CEO). "The last point is
particularly relevant because even the most advanced infant formulae
contain lower concentrations of HMOs than natural human milk." Glyn
Brookman (Director of Sales) takes up the story: "In order to replace
unnecessary HMO surrogates, like Galactooligosaccharides (GOS) and
Fructooligosaccharides (FOS), in infant formulae, the cost of HMOs
must be addressed."

Dr. Benedikt Engels (Chief Operation Officer) continues: "The new
total biosynthesis process will initially replace our current
large-scale fermentation process for the production of
2'-fucosyllactose, and will also be used to produce
lacto-N-neotetraose." Dr. Stefan Jennewein sums up the promise of the
new technology: "The introduction of our total biosynthesis concept
for HMOs is a big leap forward in our mission to bring the
significant health benefits of HMOs into every infant formula product
for the benefit of all babies."

About Jennewein Biotechnologie:

Jennewein Biotechnologie is a leading international industrial
biotechnology company with a range of products in the field of
complex oligosaccharides (HMOs) and rare monosaccharides. The company
manufactures an extensive portfolio of innovative HMO products, such
as 2'-fucosyllactose, 3'-fucosyllactose and lacto-N-tetraose. These
rare sugars are used in the food industry (particularly infant milk
formulas), the pharmaceutical industry, and the cosmetic industry.
The manufacturing process involves state-of-the-art fermentation
techniques. In 2015, the US Food and Drug Administration (FDA)
granted Jennewein Biotechnologie a license to market
2'-fucosyllactose in the USA. This was followed in 2017 by European
Union marketing authorisation under the Novel Food Regulation.

Contact:
Dr. Bettina Gutierrez
+49(0)2224-98810-797
bettina.gutierrez@jennewein-biotech.de

Original-Content von: Jennewein Biotechnologie GmbH, übermittelt durch news aktuell